The total return over the past 12 months is -78.83% vs. +16.94% for the S&P 500. So far it's up -70.05% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (78.83%) | (41.44%) | (50.86%) | N/A | N/A | N/A |
| Total Return CAGR | (78.83%) | (41.44%) | (50.86%) | N/A | N/A | N/A |
| Revenue CAGR | (68.50%) | +0.37% | +12.92% | +18.09% | (9.00%) | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Lexaria Bioscience Corp. (LEXX)
| Year | Start price | End price | LEXX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $9.25 | $2.77 | (70.05%) | +14.51% | (84.56%) |
| 2025 | $31.50 | $9.25 | (70.63%) | +17.72% | (88.35%) |
| 2024 | $18.75 | $31.50 | +68.00% | +24.89% | +43.11% |
| 2023 | $36.90 | $18.75 | (49.19%) | +26.19% | (75.38%) |
| 2022 | $60.45 | $36.90 | (38.96%) | (18.17%) | (20.79%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
